Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

CVS Caremark’s Part D Plan Acquisition Includes NCPA Partnership, For Now

Executive Summary

The Universal American Medicare Part D plans that CVS Caremark is aiming to acquire have operated through a long-standing partnership with the National Community Pharmacists Association, which would seem an awkward fit for the large drug chain.

You may also be interested in...



Medicare Part D Plans Expanding Five-Tier Formularies, Preferred Networks In 2013

A review of Part D plan design trends among the leading sponsors shows that Humana has switched to five-tier formularies, UnitedHealth is using a preferred pharmacy network and CVS Caremark is sponsoring plans that include community-based independents in its preferred network.

Medicare Part D Plans Expanding Five-Tier Formularies, Preferred Networks In 2013

A review of Part D plan design trends among the leading sponsors shows that Humana has switched to five-tier formularies, UnitedHealth is using a preferred pharmacy network and CVS Caremark is sponsoring plans that include community-based independents in its preferred network.

CVS Caremark Continues Expansion In Medicare Part D Market With Purchase From Health Net

With the acquisition, CVS Caremark would add approximately 400,000 members to its stand-alone Medicare prescription drug plan business, solidifying its position as number two in the PDP market.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS053004

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel